Holen Sie sich die Stockscreener-App
11.88
1.00%
-0.12
Handel nachbörslich:
11.88
Schlusskurs vom Vortag:
$12.00
Offen:
$12.03
24-Stunden-Volumen:
742.79K
Relative Volume:
1.06
Marktkapitalisierung:
$818.86M
Einnahmen:
$46.02M
Nettoeinkommen (Verlust:
$-70.80M
KGV:
-6.5275
EPS:
-1.82
Netto-Cashflow:
$-1.61M
1W Leistung:
+2.41%
1M Leistung:
+18.09%
6M Leistung:
+95.39%
1J Leistung:
+42.11%
1-Tages-Spanne:
$11.38
$12.07
1-Wochen-Bereich:
$11.26
$12.07
52-Wochen-Spanne:
$3.91
$13.98
Eyepoint Pharmaceuticals Inc Stock (EYPT) Company Profile
Firmenname
Eyepoint Pharmaceuticals Inc
Sektor
Branche
Telefon
617-926-5000
Adresse
480 PLEASANT STREET, WATERTOWN, MA
Vergleichen Sie EYPT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
EYPT
Eyepoint Pharmaceuticals Inc
|
11.88 | 808.52M | 46.02M | -70.80M | -1.61M | -1.82 |
|
VRTX
Vertex Pharmaceuticals Inc
|
396.93 | 102.81B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
453.54 | 58.59B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
567.22 | 61.25B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
733.66 | 43.23B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
318.73 | 36.53B | 3.81B | -644.79M | -669.77M | -6.24 |
Eyepoint Pharmaceuticals Inc Stock (EYPT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-17 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2025-01-07 | Eingeleitet | Citigroup | Buy |
| 2024-10-16 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-08-28 | Eingeleitet | Jefferies | Buy |
| 2024-01-22 | Eingeleitet | JP Morgan | Overweight |
| 2023-11-02 | Eingeleitet | Mizuho | Buy |
| 2023-04-21 | Eingeleitet | Robert W. Baird | Outperform |
| 2022-07-07 | Eingeleitet | Chardan Capital Markets | Buy |
| 2021-03-01 | Eingeleitet | Cowen | Outperform |
| 2021-01-28 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-04-06 | Herabstufung | B. Riley FBR | Buy → Neutral |
| 2019-11-04 | Fortgesetzt | Laidlaw | Buy |
| 2019-09-12 | Eingeleitet | Guggenheim | Buy |
Alle ansehen
Eyepoint Pharmaceuticals Inc Aktie (EYPT) Neueste Nachrichten
How to recover losses in EyePoint Pharmaceuticals Inc. stockBreakout Watch & Low Risk High Win Rate Picks - Newser
Multi factor analysis applied to EyePoint Pharmaceuticals Inc.July 2025 Selloffs & Verified Entry Point Detection - Newser
Volatility clustering patterns for EyePoint Pharmaceuticals Inc.Trade Risk Assessment & Long-Term Safe Return Strategies - Newser
Can a trend reversal in EyePoint Pharmaceuticals Inc. lead to recoverySell Signal & Weekly Return Optimization Plans - Newser
Is now a turning point for EyePoint Pharmaceuticals Inc.Quarterly Portfolio Review & Breakout Confirmation Trade Signals - Newser
What is the PEG ratio of EyePoint Pharmaceuticals Inc.Weekly Profit Analysis & High Accuracy Trade Alerts - khodrobank.com
News impact scoring models applied to EyePoint Pharmaceuticals Inc.2025 Dividend Review & Free Community Consensus Stock Picks - Newser
Technical analysis overview for EyePoint Pharmaceuticals Inc. stockJuly 2025 Trends & Safe Capital Growth Plans - Newser
Should I average down on EyePoint Pharmaceuticals Inc. stockInsider Selling & Verified Short-Term Trading Plans - khodrobank.com
Aug Sentiment: Why is EyePoint Pharmaceuticals Inc. stock going downJuly 2025 Summary & Consistent Return Strategy Ideas - khodrobank.com
Visual trend scoring systems applied to EyePoint Pharmaceuticals Inc.Market Sentiment Summary & Reliable Price Action Trade Plans - Newser
Real time scanner hits for EyePoint Pharmaceuticals Inc. explainedJuly 2025 Macro Moves & Capital Protection Trading Alerts - Newser
Does EyePoint Pharmaceuticals Inc. fit your quant trading model2025 Price Momentum & High Return Stock Watch Alerts - Newser
Analyzing drawdowns of EyePoint Pharmaceuticals Inc. with statistical tools2025 Price Targets & Verified Chart Pattern Trade Signals - Newser
Identifying reversal signals in EyePoint Pharmaceuticals Inc.Rate Hike & Weekly High Conviction Ideas - Newser
Will EyePoint Pharmaceuticals Inc. stock recover after recent drop2025 Key Lessons & Low Risk High Win Rate Picks - Newser
Ranking EyePoint Pharmaceuticals Inc. among high performing stocks via tools2025 Momentum Check & Free Community Consensus Stock Picks - Newser
How to integrate EyePoint Pharmaceuticals Inc. into portfolio analysis toolsMarket Sentiment Summary & Precise Swing Trade Alerts - Newser
Applying Wyckoff theory to EyePoint Pharmaceuticals Inc. stockCEO Change & Smart Money Movement Alerts - Newser
Will EyePoint Pharmaceuticals Inc. see short term momentumJuly 2025 Trends & AI Powered Buy and Sell Recommendations - Newser
Best data tools to analyze EyePoint Pharmaceuticals Inc. stockPrice Action & Risk Controlled Daily Trade Plans - Newser
Is EyePoint Pharmaceuticals Inc. stock poised for growthWeekly Volume Report & Safe Capital Growth Trade Ideas - Newser
EyePoint Pharmaceuticals Inc. stock daily chart insights2025 Top Decliners & Risk Controlled Daily Plans - Newser
EyePoint Pharmaceuticals and the Future of Retinal Disease Treatment: Assessing the Investment Potential of DURAVYU™ in a High-Growth Sector - AInvest
Should I invest in EyePoint Pharmaceuticals Inc. before earningsJuly 2025 Levels & Fast Gain Swing Alerts - خودرو بانک
Can EyePoint Pharmaceuticals Inc. lead its sector in growthRate Cut & Reliable Price Action Trade Plans - khodrobank.com
Why is EyePoint Pharmaceuticals Inc. stock going upMarket Performance Summary & Free Accurate Trade Setup Notifications - khodrobank.com
What is the long term forecast for EyePoint Pharmaceuticals Inc. stockWeekly Earnings Recap & Free Accurate Trade Setup Notifications - khodrobank.com
EyePoint Pharmaceuticals Inc. stock volume spike explainedTrade Analysis Report & Long-Term Safe Investment Plans - Newser
Can EyePoint Pharmaceuticals Inc. Escape Recent Bear Channel getLinesFromResByArray error: size == 0 - 강소기업뉴스
What’s the analyst consensus on EyePoint Pharmaceuticals Inc.M&A Rumor & Consistent Profit Trading Strategies - khodrobank.com
What to expect from EyePoint Pharmaceuticals Inc. in the next 30 daysQuarterly Trade Summary & Precise Swing Trade Alerts - Newser
Automated trading signals detected on EyePoint Pharmaceuticals Inc.Trade Exit Summary & Capital Efficient Trading Techniques - Newser
Is It Too Early to Call Recovery in EyePoint Pharmaceuticals Inc. getLinesFromResByArray error: size == 0 - 강소기업뉴스
Key metrics from EyePoint Pharmaceuticals Inc.’s quarterly data2025 Earnings Surprises & Verified Technical Trade Signals - Newser
Visualizing EyePoint Pharmaceuticals Inc. stock with heatmapsLayoff News & Community Consensus Stock Picks - Newser
Finanzdaten der Eyepoint Pharmaceuticals Inc-Aktie (EYPT)
Umsatz
Nettogewinn
Free Cashflow
ENV
Eyepoint Pharmaceuticals Inc-Aktie (EYPT) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Lurker Nancy | Director |
Jul 10 '25 |
Option Exercise |
0.00 |
11,111 |
0 |
216,547 |
| Duker Jay S. | President and CEO |
Jul 10 '25 |
Option Exercise |
0.00 |
16,667 |
0 |
17,653 |
| Elston George | Chief Financial Officer |
May 25 '25 |
Option Exercise |
0.00 |
7,500 |
0 |
83,050 |
| Zaderej Karen L. | Director |
May 19 '25 |
Buy |
5.99 |
5,000 |
29,950 |
36,500 |
| Zaderej Karen L. | Director |
May 16 '25 |
Buy |
5.81 |
5,000 |
29,050 |
31,500 |
| Zaderej Karen L. | Director |
May 15 '25 |
Buy |
5.47 |
5,000 |
27,350 |
26,500 |
| Zaderej Karen L. | Director |
May 14 '25 |
Buy |
5.42 |
5,000 |
27,100 |
21,500 |
| Elston George | Chief Financial Officer |
Feb 09 '25 |
Option Exercise |
0.00 |
5,834 |
0 |
75,550 |
| Lurker Nancy | Director |
Feb 09 '25 |
Option Exercise |
0.00 |
20,000 |
0 |
205,436 |
| Duker Jay S. | President and CEO |
Feb 09 '25 |
Option Exercise |
0.00 |
7,000 |
0 |
79,706 |
1.75%
1.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):